Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

ctDNA Carves a Precise Path for Early-Stage NSCLC Management

July 29th 2024

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

July 26th 2024

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

July 26th 2024

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

CHMP Recommends Amivantamab Plus Chemo for Pretreated EGFR+ Advanced NSCLC

July 26th 2024

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

First-Line Sugemalimab Plus Chemo Wins European Approval for Metastatic NSCLC

July 26th 2024

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

July 26th 2024

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25th 2024

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

July 25th 2024

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Atezolizumab Before and After CRT Appears Safe, Effective in Unresectable Stage III NSCLC

July 25th 2024

Atezolizumab administered before and following chemoradiation appeared to be safe and efficacious in unresectable stage III non–small cell lung cancer.

ODAC Votes to Require Within Trial Assessment of Neoadjuvant vs Adjuvant Treatment Benefit in Perioperative Trial Protocols in Resectable NSCLC

July 25th 2024

Should the FDA require that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment?

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25th 2024

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

July 25th 2024

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

July 24th 2024

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

July 24th 2024

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

July 23rd 2024

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

July 23rd 2024

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

July 23rd 2024

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

July 22nd 2024

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.

Optimizing Therapy Selection in EGFR Mutant NSCLC

July 22nd 2024

Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.

FDA Grants Fast Track Designation to ABD-147 for ES-SCLC

July 16th 2024

The FDA has awarded fast track designation to the next-generation precision radiopharmaceutical therapy ABD-147 for the treatment of patients with ES-SCLC.